# Jadenine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jadenine

- Industry: Internet
- Headquarters: China
- Website: www.jadenine.com
- Latest round: Seed (Jun 1, 2013)
- Investors on record: 1

## About

Jadenine is a biotechnology company focused on innovative genetic analysis and molecular diagnostics solutions, providing advanced tools for precise genetic testing to enhance healthcare outcomes.Jadenine specializes in biotechnology solutions that enable genetic testing and analysis. Founded in China, the company has undergone strategic pivots to enhance its product offerings. The firm received Seed financing from Microsoft Ventures in June 2013, which has supported its growth initiatives. The company operates globally, with its headquarters located in China, aiming to expand its reach in both North America and Europe. The founder of Jadenine has a background in the biotechnology sector, having previously launched other ventures, thereby contributing to the company's strategic direction.Jadenine specializes in innovative solutions within the biotechnology sector, focusing primarily on genetic analysis and molecular diagnostics. The company’s core product offerings include advanced sequencing technologies and diagnostic assays designed to facilitate precise genetic testing for various health conditions. These products serve critical use cases such as early disease detection, personalized medicine, and research applications in genomics. The target customer base includes healthcare providers, research institutions, and pharmaceutical companies operating in North America and Europe. The company has positioned itself to address the growing demand for accurate and efficient genetic testing solutions, and its products are utilized by professionals seeking to enhance patient care and streamline research processes.Jadenine generates revenue through a combination of direct sales and strategic partnerships within the biotechnology sector. The typical transaction model involves B2B engagements where healthcare facilities and research organizations purchase diagnostic assays and sequencing services. Revenue is structured through service agreements, with clients often entering into multi-year contracts to ensure ongoing access to Jadenine's proprietary technologies. Specific pricing plans are established based on the scale and scope of services provided, reflecting the complexity and customization of the genetic tests offered. The company's flagship products, known for their robustness and reliability, play a significant role in driving these transactions, contributing to sustained revenue growth from both established and emerging markets.Jadenine plans to launch new products in the upcoming years, focusing on advancements in genetic testing technologies to improve accuracy and efficiency. The company has identified markets in North America and Europe for expansion, aiming to establish a stronger presence by 2025. The Seed financing received from Microsoft Ventures in June 2013 is expected to play a crucial role in supporting these growth initiatives, enabling the development of new products and the exploration of new market opportunities.

## Funding rounds

- Seed, Jun 1, 2013 — M12

## Investors

- M12 (https://capitalatlas.ai/funds/m12) — Seed